H

Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566

Watchlist Manager
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Watchlist
Price: 30.78 CNY -2.84% Market Closed
Market Cap: 28.2B CNY
Have any thoughts about
Hubei Jumpcan Pharmaceutical Co Ltd?
Write Note

Hubei Jumpcan Pharmaceutical Co Ltd
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hubei Jumpcan Pharmaceutical Co Ltd
Research & Development Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Research & Development
-ÂĄ457.5m
CAGR 3-Years
-20%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Research & Development
-ÂĄ2.1B
CAGR 3-Years
-19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Research & Development
-ÂĄ232.3m
CAGR 3-Years
-31%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Research & Development
-ÂĄ5.7B
CAGR 3-Years
0%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Research & Development
-ÂĄ339.2m
CAGR 3-Years
-19%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Research & Development
-ÂĄ712.5m
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Hubei Jumpcan Pharmaceutical Co Ltd's Research & Development?
Research & Development
-457.5m CNY

Based on the financial report for Jun 30, 2024, Hubei Jumpcan Pharmaceutical Co Ltd's Research & Development amounts to -457.5m CNY.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-24%

Over the last year, the Research & Development growth was 23%. The average annual Research & Development growth rates for Hubei Jumpcan Pharmaceutical Co Ltd have been -20% over the past three years , -24% over the past five years .

Back to Top